Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- In Yet Another Setback, Daiichi Sankyo’s Tivantinib Fails Liver Cancer PIII
February 21, 2017
- Rexulti Approved in Canada: Otsuka
February 21, 2017
- Takeda’s Cx601 Stem Cell Therapy Shows Long-Term Effect
February 21, 2017
- Entyvio Delivers 95%-Plus Clinical Response for UC, CD at 5 Years
February 21, 2017
- Look at Value-Based Price Gap, Not Percentages, Sawai Says on Partial Revisions
February 20, 2017
- EA Pharma President Shimizu Dies at 59
February 20, 2017
- Takeda’s Ariad Acquisition Completed
February 20, 2017
- Chugai Files PD-L1 Inhibitor Atezolizumab in Japan
February 20, 2017
- Osaka Univ. Inks Another 10-Year Immunology Pact, This Time with Otsuka
February 17, 2017
- Eisai Gets Rights for 2 Orion Parkinson’s Meds in China
February 17, 2017
- Takecab Most Heavily Promoted Drug in HP Market in December: Anterio
February 16, 2017
- Takeda, PRA to Launch JV in Japan to Take Over 140 Employees
February 16, 2017
- Ono Looks for New Growth through Opdivo Despite NHI Price Cut: President
February 16, 2017
- Bristol-Myers Looks to Crack into Genotype 1 Hep C Market as Ximency Clears Resistance Mutation Hurdle
February 15, 2017
- Keytruda Now Available in Japan
February 15, 2017
- AbbVie’s 8-Week Hep C Therapy Filed in Japan
February 15, 2017
- Otsuka Aims for Abilify Maintena’s 30% Share in LAI Antipsychotic Market
February 15, 2017
- Otsuka’s 2016 Earnings Falter as Abilify Sales Dive 70%
February 15, 2017
- Bisphosphonates Grab Top Share, PTH Preparations Expand in FY2015 Osteoporosis Market: Report
February 14, 2017
- Test Urine Copper in Pregnant Women Taking Nobelzin: Nobelpharma
February 14, 2017
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…